FDA approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine
31/08/2022
Lundbeck today announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive… read more >